From concept and formulation to regulatory batches and commercial supply, one integrated path.
We strategically invest in developing and commercializing a differentiated portfolio of niche, high-complexity pharmaceuticals — leveraging an experienced R&D team and a network of reliable CMO and CRO partners to drive a pipeline built to address real medical needs.
Co-development and co-investment can begin from Stage 2.
Molecules are evaluated against unmet need, market attractiveness, regulatory feasibility, competitive barriers, and licensing potential before development begins.
Complex injectable, sterile, and advanced-delivery formulations are engineered to create real clinical and commercial differentiation.
Formulations are scaled and prepared for clinical development under defined, capital-efficient regulatory pathways. At the end of this stage the asset is in a licensable state.
Following licensing or a co-development agreement, the asset package and process transfer to the partner or its chosen manufacturing site.
Registration and validation batches are manufactured under GMP conditions to support regulatory submission requirements.
Approved products transition to commercial-scale manufacturing and ongoing supply, through our CMO network or the licensee's site.
Off Targets programs are developed under 505(b)(2) and other defined regulatory pathways that allow a new formulation of a known molecule to rely, in part, on existing safety and efficacy data — rather than building a full clinical package from first principles.
A 505(b)(2) pathway does not by itself confer market exclusivity. Protection is designed into each program deliberately, from several sources.
Where a program generates new clinical investigations essential to approval, FDA may grant a period of three-year exclusivity for that change. Programs in orphan-designated indications may qualify for seven years.
Formulation, process and delivery innovations are protected through our own patent filings, assessed alongside the patent landscape of each reference product.
Complex injectables and advanced-delivery formulations are harder to replicate than conventional dosage forms, which limits fast followers independent of any exclusivity period.
Eligibility is assessed case by case against FDA criteria and varies by program and jurisdiction.
Regulatory strategy only creates value if it's executed and maintained — from first filing through the life of the approval.